As clinical development grows more complex and globally interconnected, biotech companies are under increasing pressure to build CRO partnerships that deli...
Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), is pleased to announ...
PrognomiQ, a healthcare company focused on harnessing the power of proteomics and multi-omics data to transform the detection and early treatment selecti...
- AOP Health, a global pharmaceutical enterprise group focused on integrated therapies for rare diseases and critical care, announced a strategic pa...
Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stag...
Partnership combines venture creation and biologics discovery to accelerate novel medicines through human clinical proof of concept First-of-its-kind ...
Roche has received CE Mark approval for Elecsys® pTau217, a blood-based diagnostic test designed to detect phosphorylated Tau (pTau) 217 protein, a k...
Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inha...
Amplia and ANZGOG enter into agreement to conduct a clinical study in ovarian cancer evaluating narmafotinib in combination with standard-of-care chemo...
New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms. In return for...
Marks first ENHANZE® agreement to include ADC targets Collaboration also includes option for additional future targets First cl...
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development p...
Transaction Adds Dual BBB Delivery Strategies, Supports Alzheimer's Programs, Combination Therapies, 505(b)(2) Pathways, and CNS Countermeasure Applicati...
FreeMind Investments (FMI), a venture capital fund launched in partnership between FreeMind Group and Daewoong Pharmaceutical Co., Ltd., announced its in...
© 2026 Biopharma Boardroom. All Rights Reserved.
